Toggle Sidebar
Home
AI Agent
Annotations
Files
Pricing and plans
Help
Blog
About
Contact us
API
MCP
Terms of service
Privacy policy
Get the full experience
We save the real magic for signed-in users.
Sign In
IBRX US
Home
Stock Screener
Document Search
Charting
Watchlists
Recent Filings
ImmunityBio, Inc.
(IBRX US)
$5.91
-0.16
2.67%
(Market Open · 17:32:43 UTC)
Ask AI
Follow
Doc Search
Profile
Entity Structure
SEC Filings
Financials
Charting
Short Interest
Employees
Toggle Sidebar
Home
AI Agent
Annotations
Files
Pricing and plans
Help
Blog
About
Contact us
API
MCP
Terms of service
Privacy policy
Get the full experience
We save the real magic for signed-in users.
Sign In
IBRX US
Home
Stock Screener
Document Search
Charting
Watchlists
Recent Filings
ImmunityBio, Inc.
(IBRX US)
$5.91
-0.16
2.67%
(Market Open · 17:32:43 UTC)
Ask AI
Follow
Doc Search
Profile
Entity Structure
SEC Filings
Financials
Charting
Short Interest
Employees
Chronological
By Owner
Financials & Metrics
Financials
Charting
Short Interest
Employees
Chronological
By Owner
Financials & Metrics
Financials
Charting
Short Interest
Employees
SEC Filings
SEC Filings
Select Filings
Financials
(46)
Expand
10-Q
Q3
ended 30 Sept 2026
9 Nov
10-Q
Q2
ended 30 Jun 2026
4 Aug
10-Q
Q1
ended 31 Mar 2026
7 May
10-K
FY 2025
ended 31 Dec 2025
23 Feb
10-Q
Q3
ended 30 Sept 2025
4 Nov 2025
10-Q
Q2
ended 30 Jun 2025
5 Aug 2025
10-Q
Q1
ended 31 Mar 2025
12 May 2025
10-K
FY 2024
ended 31 Dec 2024
3 Mar 2025
10-Q
Q3
ended 30 Sept 2024
12 Nov 2024
10-Q
Q2
ended 30 Jun 2024
12 Aug 2024
10-Q
Q1
ended 31 Mar 2024
9 May 2024
10-K
FY 2023
ended 31 Dec 2023
19 Mar 2024
10-Q
Q3
ended 30 Sept 2023
9 Nov 2023
10-Q
Q2
ended 30 Jun 2023
8 Aug 2023
10-Q
Q1
ended 31 Mar 2023
11 May 2023
Events
(102)
Expand
8-K
Results of Operations and Financial Condition
9 Nov
8-K
Regulation FD Disclosure
9 Nov
8-K
FDA Expands ANKTIVA®Approval forBCG-UnresponsiveNon-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
14 Oct
8-K
Results of Operations and Financial Condition
4 Aug
8-K
Regulation FD Disclosure
30 Jul
8-K
Submission of Matters to a Vote of Security Holders
10 Jun
8-K
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
18 May
8-K
Results of Operations and Financial Condition
7 May
8-K
Results of Operations and Financial Condition
9 Apr
8-K
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
6 Apr
8-K
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million ofNon-DilutiveFinancing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
31 Mar
8-K
Results of Operations and Financial Condition
23 Feb
8-K
Other Events
18 Feb
8-K
Entry into a Material Definitive Agreement
26 Jan
8-K
Results of Operations and Financial Condition
15 Jan
Insider Ownership
(251)
Expand
Form 4
Simon Barry J.
6 Oct
Form 4
Cohen Cheryl
6 Oct
Form 4
Cohen Cheryl
6 Jul
Form 4
Selecky Christobel
6 Jul
Form 4
Selecky Christobel
1 Jul
Form 4
Simon Barry J.
26 Jun
Form 4
BLASZYK MICHAEL D
10 Jun
Form 4
Wendel Bruce
10 Jun
Form 4
MAXWELL LINDA
10 Jun
Form 4
Clark Wesley
10 Jun
Form 4
Cohen Cheryl
10 Jun
Form 4
Selecky Christobel
10 Jun
Form 4
Simon Barry J.
5 Jun
Form 4
Nant Capital, LLC
2 Apr
Form 4
Simon Barry J.
26 Feb
Beneficial Ownership
(19)
Expand
SC 13D/A
ImmunityBio, Inc.
6 Aug
SC 13D/A
ImmunityBio, Inc.
25 Feb
SC 13D/A
ImmunityBio, Inc.
10 Nov 2025
SC 13D/A
ImmunityBio, Inc.
4 Jan 2024
SC 13D/A
ImmunityBio, Inc.
21 Sep 2023
SC 13D/A
ImmunityBio, Inc.
23 May 2023
SC 13D/A
ImmunityBio, Inc.
7 Dec 2022
SC 13D/A
ImmunityBio, Inc.
12 Mar 2021
SC 13D/A
NantKwest, Inc.
21 Dec 2020
SC 13D/A
NantKwest, Inc.
29 Jun 2020
SC 13D/A
NantKwest, Inc.
1 Apr 2019
SC 13G
NantKwest, Inc.
13 Feb 2018
SC 13G/A
NantKwest, Inc.
13 Feb 2018
SC 13G/A
NantKwest, Inc.
13 Feb 2017
SC 13D/A
NantKwest, Inc.
11 Jul 2016
Other Ownership
(11)
Expand
Form 144
Simon Barry J.
5 Oct
Form 144
Cohen Cheryl
2 Oct
Form 144
Cohen Cheryl
2 Jul
Form 144
Selecky Christobel
1 Jul
Form 144
Selecky Christobel
30 Jun
Form 144
Selecky Christobel
29 Jun
Form 144
Simon Barry J.
4 Jun
Form 144
Selecky Christobel
23 Feb
Form 144
Selecky Christobel
20 Jan
Form 144
Simon Barry J.
20 Jan
Form 144
Selecky Christobel
16 Jan
Proxies
(27)
Expand
DEFA14A
Definitive additional materials
29 Apr
DEF 14A
Definitive proxy statement
29 Apr
ARS
Annual report to security holders
29 Apr
DEF 14C
Definitive information statement
20 Oct 2025
PRE 14C
Preliminary information statement
8 Oct 2025
DEFA14A
Definitive additional materials
30 Apr 2025
ARS
Annual report to security holders
30 Apr 2025
DEF 14A
Definitive proxy statement
30 Apr 2025
DEFA14A
Definitive additional materials
29 Apr 2024
DEF 14A
Definitive proxy statement
29 Apr 2024
ARS
Annual report to security holders
29 Apr 2024
DEF 14C
Definitive information statement
28 Sep 2023
PRE 14C
Preliminary information statement
18 Sep 2023
DEF 14A
Definitive proxy statement
28 Apr 2023
ARS
Annual report to security holders
28 Apr 2023
Registrations
(60)
Expand
424B5
Prospectus filing (Rule 424(b)(5))
23 Dec 2025
424B5
Prospectus filing (Rule 424(b)(5))
28 Jul 2025
S-8
Registration statement (employee benefit plan)
23 Jun 2025
424B5
Prospectus filing (Rule 424(b)(5))
8 Apr 2025
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2024
424B5
Prospectus filing (Rule 424(b)(5))
10 Dec 2024
S-8
Registration statement (employee benefit plan)
20 Jun 2024
S-3ASR
Automatic shelf registration statement (S-3)
17 Apr 2024
424B5
Prospectus filing (Rule 424(b)(5))
25 Jul 2023
424B5
Prospectus filing (Rule 424(b)(5))
24 Jul 2023
424B5
Prospectus filing (Rule 424(b)(5))
16 Feb 2023
S-3
Registration statement (primary offering)
7 Feb 2023
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2022
S-3MEF
Registration statement (additional securities, S-3)
12 Dec 2022
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2022
Filing Review Correspondence
(13)
Expand
CORRESP
Filing review correspondence
30 Apr 2024
CORRESP
Filing review correspondence
28 Mar 2024
CORRESP
Filing review correspondence
8 Feb 2023
CORRESP
Filing review correspondence
5 Jan 2023
CORRESP
Filing review correspondence
29 Aug 2019
CORRESP
Filing review correspondence
23 Aug 2016
CORRESP
Filing review correspondence
24 Jul 2015
CORRESP
Filing review correspondence
24 Jul 2015
CORRESP
Filing review correspondence
15 Jul 2015
CORRESP
Filing review correspondence
13 Jul 2015
CORRESP
Filing review correspondence
6 Jul 2015
CORRESP
Filing review correspondence
2 Jul 2015
CORRESP
Filing review correspondence
19 Jun 2015
SEC Orders And Notices
(9)
Expand
EFFECT
Notice of effectiveness
2 May 2024
EFFECT
Notice of effectiveness
9 Feb 2023
EFFECT
Notice of effectiveness
18 May 2022
EFFECT
Notice of effectiveness
26 May 2021
EFFECT
Notice of effectiveness
1 Feb 2021
EFFECT
Notice of effectiveness
3 Sep 2019
EFFECT
Notice of effectiveness
26 Aug 2016
CT ORDER
Confidential treatment order
28 Jul 2015
EFFECT
Notice of effectiveness
27 Jul 2015
Exempt Offerings
(9)
Expand
D
06b
22 Sep 2023
D
06b
22 Jul 2022
D
06b
5 Aug 2015
D/A
06b
17 Jul 2015
D
06b
24 Jun 2015
D
06b
5 Jan 2015
D
06b
29 Dec 2014
D
06b
17 Apr 2014
D
Notice of exempt offering of securities (Reg D)
9 Oct 2009
Other
(1)
Expand
CERTNAS
AUTO-GENERATED PAPER DOCUMENT
24 Jul 2015
Select Filings
Financials
(46)
Expand
10-Q
Q3
ended 30 Sept 2026
9 Nov
10-Q
Q2
ended 30 Jun 2026
4 Aug
10-Q
Q1
ended 31 Mar 2026
7 May
10-K
FY 2025
ended 31 Dec 2025
23 Feb
10-Q
Q3
ended 30 Sept 2025
4 Nov 2025
10-Q
Q2
ended 30 Jun 2025
5 Aug 2025
10-Q
Q1
ended 31 Mar 2025
12 May 2025
10-K
FY 2024
ended 31 Dec 2024
3 Mar 2025
10-Q
Q3
ended 30 Sept 2024
12 Nov 2024
10-Q
Q2
ended 30 Jun 2024
12 Aug 2024
10-Q
Q1
ended 31 Mar 2024
9 May 2024
10-K
FY 2023
ended 31 Dec 2023
19 Mar 2024
10-Q
Q3
ended 30 Sept 2023
9 Nov 2023
10-Q
Q2
ended 30 Jun 2023
8 Aug 2023
10-Q
Q1
ended 31 Mar 2023
11 May 2023
Events
(102)
Expand
8-K
Results of Operations and Financial Condition
9 Nov
8-K
Regulation FD Disclosure
9 Nov
8-K
FDA Expands ANKTIVA®Approval forBCG-UnresponsiveNon-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
14 Oct
8-K
Results of Operations and Financial Condition
4 Aug
8-K
Regulation FD Disclosure
30 Jul
8-K
Submission of Matters to a Vote of Security Holders
10 Jun
8-K
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
18 May
8-K
Results of Operations and Financial Condition
7 May
8-K
Results of Operations and Financial Condition
9 Apr
8-K
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
6 Apr
8-K
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million ofNon-DilutiveFinancing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
31 Mar
8-K
Results of Operations and Financial Condition
23 Feb
8-K
Other Events
18 Feb
8-K
Entry into a Material Definitive Agreement
26 Jan
8-K
Results of Operations and Financial Condition
15 Jan
Insider Ownership
(251)
Expand
Form 4
Simon Barry J.
6 Oct
Form 4
Cohen Cheryl
6 Oct
Form 4
Cohen Cheryl
6 Jul
Form 4
Selecky Christobel
6 Jul
Form 4
Selecky Christobel
1 Jul
Form 4
Simon Barry J.
26 Jun
Form 4
BLASZYK MICHAEL D
10 Jun
Form 4
Wendel Bruce
10 Jun
Form 4
MAXWELL LINDA
10 Jun
Form 4
Clark Wesley
10 Jun
Form 4
Cohen Cheryl
10 Jun
Form 4
Selecky Christobel
10 Jun
Form 4
Simon Barry J.
5 Jun
Form 4
Nant Capital, LLC
2 Apr
Form 4
Simon Barry J.
26 Feb
Beneficial Ownership
(19)
Expand
SC 13D/A
ImmunityBio, Inc.
6 Aug
SC 13D/A
ImmunityBio, Inc.
25 Feb
SC 13D/A
ImmunityBio, Inc.
10 Nov 2025
SC 13D/A
ImmunityBio, Inc.
4 Jan 2024
SC 13D/A
ImmunityBio, Inc.
21 Sep 2023
SC 13D/A
ImmunityBio, Inc.
23 May 2023
SC 13D/A
ImmunityBio, Inc.
7 Dec 2022
SC 13D/A
ImmunityBio, Inc.
12 Mar 2021
SC 13D/A
NantKwest, Inc.
21 Dec 2020
SC 13D/A
NantKwest, Inc.
29 Jun 2020
SC 13D/A
NantKwest, Inc.
1 Apr 2019
SC 13G
NantKwest, Inc.
13 Feb 2018
SC 13G/A
NantKwest, Inc.
13 Feb 2018
SC 13G/A
NantKwest, Inc.
13 Feb 2017
SC 13D/A
NantKwest, Inc.
11 Jul 2016
Other Ownership
(11)
Expand
Form 144
Simon Barry J.
5 Oct
Form 144
Cohen Cheryl
2 Oct
Form 144
Cohen Cheryl
2 Jul
Form 144
Selecky Christobel
1 Jul
Form 144
Selecky Christobel
30 Jun
Form 144
Selecky Christobel
29 Jun
Form 144
Simon Barry J.
4 Jun
Form 144
Selecky Christobel
23 Feb
Form 144
Selecky Christobel
20 Jan
Form 144
Simon Barry J.
20 Jan
Form 144
Selecky Christobel
16 Jan
Proxies
(27)
Expand
DEFA14A
Definitive additional materials
29 Apr
DEF 14A
Definitive proxy statement
29 Apr
ARS
Annual report to security holders
29 Apr
DEF 14C
Definitive information statement
20 Oct 2025
PRE 14C
Preliminary information statement
8 Oct 2025
DEFA14A
Definitive additional materials
30 Apr 2025
ARS
Annual report to security holders
30 Apr 2025
DEF 14A
Definitive proxy statement
30 Apr 2025
DEFA14A
Definitive additional materials
29 Apr 2024
DEF 14A
Definitive proxy statement
29 Apr 2024
ARS
Annual report to security holders
29 Apr 2024
DEF 14C
Definitive information statement
28 Sep 2023
PRE 14C
Preliminary information statement
18 Sep 2023
DEF 14A
Definitive proxy statement
28 Apr 2023
ARS
Annual report to security holders
28 Apr 2023
Registrations
(60)
Expand
424B5
Prospectus filing (Rule 424(b)(5))
23 Dec 2025
424B5
Prospectus filing (Rule 424(b)(5))
28 Jul 2025
S-8
Registration statement (employee benefit plan)
23 Jun 2025
424B5
Prospectus filing (Rule 424(b)(5))
8 Apr 2025
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2024
424B5
Prospectus filing (Rule 424(b)(5))
10 Dec 2024
S-8
Registration statement (employee benefit plan)
20 Jun 2024
S-3ASR
Automatic shelf registration statement (S-3)
17 Apr 2024
424B5
Prospectus filing (Rule 424(b)(5))
25 Jul 2023
424B5
Prospectus filing (Rule 424(b)(5))
24 Jul 2023
424B5
Prospectus filing (Rule 424(b)(5))
16 Feb 2023
S-3
Registration statement (primary offering)
7 Feb 2023
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2022
S-3MEF
Registration statement (additional securities, S-3)
12 Dec 2022
424B5
Prospectus filing (Rule 424(b)(5))
12 Dec 2022
Filing Review Correspondence
(13)
Expand
CORRESP
Filing review correspondence
30 Apr 2024
CORRESP
Filing review correspondence
28 Mar 2024
CORRESP
Filing review correspondence
8 Feb 2023
CORRESP
Filing review correspondence
5 Jan 2023
CORRESP
Filing review correspondence
29 Aug 2019
CORRESP
Filing review correspondence
23 Aug 2016
CORRESP
Filing review correspondence
24 Jul 2015
CORRESP
Filing review correspondence
24 Jul 2015
CORRESP
Filing review correspondence
15 Jul 2015
CORRESP
Filing review correspondence
13 Jul 2015
CORRESP
Filing review correspondence
6 Jul 2015
CORRESP
Filing review correspondence
2 Jul 2015
CORRESP
Filing review correspondence
19 Jun 2015
SEC Orders And Notices
(9)
Expand
EFFECT
Notice of effectiveness
2 May 2024
EFFECT
Notice of effectiveness
9 Feb 2023
EFFECT
Notice of effectiveness
18 May 2022
EFFECT
Notice of effectiveness
26 May 2021
EFFECT
Notice of effectiveness
1 Feb 2021
EFFECT
Notice of effectiveness
3 Sep 2019
EFFECT
Notice of effectiveness
26 Aug 2016
CT ORDER
Confidential treatment order
28 Jul 2015
EFFECT
Notice of effectiveness
27 Jul 2015
Exempt Offerings
(9)
Expand
D
06b
22 Sep 2023
D
06b
22 Jul 2022
D
06b
5 Aug 2015
D/A
06b
17 Jul 2015
D
06b
24 Jun 2015
D
06b
5 Jan 2015
D
06b
29 Dec 2014
D
06b
17 Apr 2014
D
Notice of exempt offering of securities (Reg D)
9 Oct 2009
Other
(1)
Expand
CERTNAS
AUTO-GENERATED PAPER DOCUMENT
24 Jul 2015
Ask in Filing
Ask in Filing
